Core Insights - Humana reported $32.65 billion in revenue for Q3 2025, an 11.4% year-over-year increase, with an EPS of $3.24 compared to $4.16 a year ago, indicating a decline in earnings per share [1] - The revenue exceeded the Zacks Consensus Estimate of $31.98 billion by 2.09%, and the EPS surpassed the consensus estimate of $2.91 by 11.34% [1] Financial Performance Metrics - Benefits Expense Ratio was reported at 91.1%, slightly above the average estimate of 90.9% [4] - Medical Membership in Medicare stand-alone PDP was 2.45 million, slightly below the estimated 2.46 million [4] - Medical Membership for State-based contracts and others was 1.66 million, slightly above the estimate of 1.65 million [4] - Group Medicare Advantage Medical Membership reached 569.8 thousand, exceeding the estimate of 558.84 thousand [4] - Investment income was reported at $338 million, surpassing the estimate of $271.05 million, but reflecting a -1.5% change year-over-year [4] - Premium revenues were $30.71 billion, above the estimate of $30.35 billion, showing a +9.9% change year-over-year [4] - Service revenues were $1.6 billion, exceeding the average estimate of $1.39 billion, representing a +45.1% year-over-year change [4] - Military services and other insurance segment revenues were $267 million, above the estimate of $222.94 million, with a +24.8% year-over-year change [4] - CenterWell segment revenue was $5.88 billion, exceeding the estimate of $5.49 billion, reflecting a +16.6% year-over-year change [4] - Total services revenue for CenterWell segment was $1.33 billion, surpassing the estimate of $1.17 billion, indicating a +52% year-over-year change [4] - Pharmacy solutions revenue within CenterWell segment was $352 million, slightly above the estimate of $349.81 million [4] Stock Performance - Humana's shares have returned -4.5% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Core Insights - CVS Health's Health Care Benefits segment reported strong performance in Q2 2025, with revenues exceeding $36 billion, reflecting an over 11% increase year-over-year, primarily driven by government business growth influenced by the 2022 Inflation Reduction Act [1][8] - The company plans to exit the individual exchange business in 2026, anticipating variable losses between $350 million and $400 million for 2025 due to ongoing performance challenges [2][8] - CVS recorded a $471 million premium deficiency reserve related to its Group Medicare Advantage product line, raising the medical benefit ratio to 89.9%, a 30-basis-point increase from the previous year [3][4] Financial Performance - The adjusted operating income for CVS Health surged nearly 40%, benefiting from favorable changes in individual exchange risk adjustment estimates and stronger government business performance [1][8] - Medical membership as of June 30 decreased to 26.7 million, attributed to expected declines following the expiration of a premium grace period [2] - Days' claims payable improved to 40.9 days, a reduction of approximately 2 days sequentially, driven by a higher mix of pharmacy costs [4] Competitive Landscape - Elevance Health reported Q2 2025 operating revenues of $41.6 billion, a 12% year-over-year increase, mainly due to higher premium yields and growth in Medicare Advantage membership [5] - Humana's performance was bolstered by its CenterWell pharmacy and improved individual Medicare Advantage membership, alongside strategic Medicaid expansion efforts [6] Stock Performance and Valuation - CVS Health shares have appreciated by 27.5% over the past year, contrasting with a 16.7% decline in the industry [7] - The company is currently trading at a forward five-year earnings multiple of 10.65, below the industry average of 15.33, and holds a Value Score of A [9] - Consensus estimates for CVS's earnings in 2025 and 2026 show a bullish trend, with current estimates at 6.32 for 2025 and 7.14 for 2026 [10][11]

Core Insights - Humana (HUM) is expected to report quarterly earnings of $6.32 per share, reflecting a decline of 9.2% year over year, while revenues are forecasted to reach $31.78 billion, an increase of 8.2% year over year [1] Earnings Estimates - Analysts have revised the consensus EPS estimate down by 0.1% over the past 30 days, indicating a collective reassessment of projections [1][2] Revenue Breakdown - 'Revenues- Premiums' are projected to be $30.23 billion, showing a year-over-year increase of 7.4% [4] - 'Revenues- Services' are estimated at $1.31 billion, indicating a significant year-over-year growth of 19% [4] - 'Revenues- Investment income (loss)' is expected to be $270.96 million, reflecting a decline of 9.1% from the previous year [4] - 'Revenue- Insurance' is anticipated to reach $30.71 billion, marking a 7.7% increase from the prior year [5] Membership Metrics - 'Medical Membership - Medicare stand-alone PDP' is projected to reach 2.45 million, up from 2.34 million in the same quarter last year [6] - 'Medical Membership - State-based contracts and other' is expected to be 1.62 million, compared to 1.39 million a year ago [6] - 'Medical Membership - Group Medicare Advantage' is estimated at 562.63 thousand, an increase from 544.90 thousand year-over-year [7] - 'Medical Membership - Medicare Supplement' is forecasted to reach 419.63 thousand, up from 339.20 thousand in the same quarter last year [7] - 'Medical Membership - Individual Medicare Advantage' is expected to decline to 5.18 million from 5.62 million year-over-year [8] - Total 'Medical Membership - Total Medicare' is projected at 8.19 million, down from 8.50 million a year ago [8] - 'Medical Membership - Military services' is estimated to be 4.94 million, compared to 5.96 million in the previous year [9] Stock Performance - Humana shares have decreased by 1.6% over the past month, contrasting with a 4.9% increase in the Zacks S&P 500 composite [9]